Ngm Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

SOUTH SAN FRANCISCO, Calif., Aug.  29, 2020  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that final data from its 24-week Phase 2 study (Cohort 4) of aldafermin 1 mg in patients with non-alcoholic steatohepatitis (NASH) were featured in a late-breaker oral plenary presentation today (LBO-01) at The Digital International Liver Congress™ (ILC) 2020. The presentation included a new analysis of Cohort 4 data from NASH patients with stage 3 liver fibrosis (F3) demonstrating that 1 mg aldafermin had a potent anti-fibrotic effect in these patients with more advanced disease. NGM also announced today that it has completed enrollment in its ongoing Phase 2b ALPINE 2/3 study of 0.3 mg, 1 mg and 3 mg aldafermin versus placebo in patients with biopsy-confirmed NASH with stage 2 (F2) and F3 liver fibrosis. The primary objective of the ALPINE 2/3 study is to evaluate a dose response showing an improvement in liver fibrosis by ≥ 1 stage with no worsening of steatohepatitis at Week 24. NGM expects to report topline findings from the study in the second quarter of 2021.

NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study

SOUTH SAN FRANCISCO, Calif., Aug.  18, 2020  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that comprehensive data from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients with non-alcoholic steatohepatitis (NASH) will be featured in an oral plenary presentation at The Digital International Liver Congress (ILC) 2020, which will be held virtually August 27-29, 2020.

NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of  Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020

--Sustained progress across clinical development programs spanning liver,  retinal and metabolic diseases and cancer--   --Aldafermin continues to advance toward late-stage clinical development in non-alcoholic  steatohepatitis (NASH) with ongoing Phase 2b ALPINE 2/3 and ALPINE 4 clinical studies--

NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results

NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NGM Biopharmaceuticals (NGM) to Report a Decline in Earnings: What to Look Out for

SOUTH SAN FRANCISCO, Calif., July  31, 2020  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at two upcoming investor conferences.

NGM Bio to Present at Two Upcoming Investor Conferences

-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks --  -- GA is a progressive, irreversible retinal degenerative disease with no approved therapies --

NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

NGM Biopharmaceuticals (NGM) Soars: Stock Adds 7.8% in Session

SOUTH SAN FRANCISCO, Calif., May  27, 2020  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced the appointment of Siobhan Nolan Mangini as Chief Financial Officer (CFO). In her role as CFO, which will take effect on July 13, 2020, Ms. Nolan Mangini will oversee finance, business development and investor relations at NGM.  

NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer

-- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in   non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) --   -- Continuing enrollment in Phase 2b ALPINE 2/3 clinical study of aldafermin in NASH patients with   F2-F3 fibrosis; topline data readout still targeted for first half of 2021 --

NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., May  08, 2020  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that, due to public health and safety concerns related to the coronavirus (COVID-19) pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual Meeting of Stockholders (“Annual Meeting”) as a virtual-only meeting that will be held via live audio webcast. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.

NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

Accelerate Diagnostics

Cardlytics

G-III Apparel Group

OPKO Health

Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.

Corporate Insiders Pull the Trigger on These 5 Stocks

NGM Biopharmaceuticals Inc (NASDAQ: NGM), which went public about a year back, has seen its shares trade mostly below the IPO price of $16.

Analyst Projects Over 130% Upside In This Biopharma

SOUTH SAN FRANCISCO, Calif., March  09, 2020  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that, effective March 13, 2020, Aetna Wun Trombley, Ph.D. will step down as President and Chief Operating Officer (COO) of the company to assume the role of Chief Executive Officer at an undisclosed privately held company. Dr. Trombley will continue with NGM on a consulting basis for an interim period to help on strategic topics and to provide operational continuity during the transition process.

Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company

Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.

NGM Biopharmaceuticals Reports a Successful NASH Trial

Shares popped after the clinical-stage biotech reported upbeat clinical results.

Here's Why NGM Biopharmaceuticals Is Soaring Today

NGM Biopharmaceuticals Inc (NASDAQ: NGM) is advancing strongly on above-average volume Monday following a positive clinical data readout.

NGM Biopharma Shares Spike Higher On Positive NASH Study Results

--Study to evaluate potential of GDF15/GFRAL pathway inhibition to  block tumor-associated weight loss and tumor growth-- --CACS, an uncontrolled wasting syndrome, is a common co-morbidity of cancer and  associated with shortened survival--

NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)

SOUTH SAN FRANCISCO, Calif., Dec.  05, 2019  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced the expansion of its Board of Directors with the appointment of Shelly Guyer, who currently serves as Chief Financial Officer (CFO) of Invitae Corporation (NYSE: NVTA).

NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.

NGM Biopharmaceuticals Shares March Higher, Can It Continue?

AC Immune

Ascendis Pharma

Eyenovia

SAGE Therapeutics

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

5 Biotech Stocks Set to Beat Q3 Earnings Estimates

NGM Biopharmaceuticals announces positive data from Phase 2b study treating patients with NASH using NGM282.

NGM NASH Data Was Preliminary, But More Important Biopsy Data On Its Way Early 2020

SOUTH SAN FRANCISCO, Calif., Oct.  18, 2019  (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today announced that it will present at two upcoming conferences focused on drug research and development for non-alcoholic steatohepatitis (NASH). NGM’s lead clinical candidate, aldafermin (formerly known as NGM282), is currently in Phase 2b clinical development for the treatment of NASH.  Presentation details are as follows:

NGM Bio to Present at Upcoming Investor Conferences

Aurora Cannabis

Sorrento Therapeutics Inc

Tough industry conditions and company-specific issues hit these stocks.

News for Ngm Biopharmaceuticals Inc Stock (NGM)